Pacific Capital Partners Ltd Increases Stake in Humana Inc. $HUM

Pacific Capital Partners Ltd raised its holdings in Humana Inc. (NYSE:HUM) by 35.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,500 shares of the insurance provider’s stock after buying an additional 3,500 shares during the period. Humana makes up approximately 3.7% of Pacific Capital Partners Ltd’s portfolio, making the stock its 12th largest position. Pacific Capital Partners Ltd’s holdings in Humana were worth $3,458,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. CoreCap Advisors LLC raised its stake in shares of Humana by 54.4% in the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 37 shares in the last quarter. Rosenberg Matthew Hamilton grew its stake in Humana by 136.0% during the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 68 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in Humana during the 2nd quarter worth about $32,000. Mather Group LLC. purchased a new stake in Humana during the 3rd quarter worth about $34,000. Finally, Private Wealth Management Group LLC raised its position in Humana by 47.5% in the 3rd quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock valued at $39,000 after purchasing an additional 48 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insiders Place Their Bets

In related news, insider Sanjay K. Shetty purchased 810 shares of Humana stock in a transaction that occurred on Monday, February 23rd. The stock was purchased at an average cost of $185.21 per share, with a total value of $150,020.10. Following the completion of the transaction, the insider directly owned 11,657 shares in the company, valued at approximately $2,158,992.97. The trade was a 7.47% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is currently owned by company insiders.

Humana Price Performance

Shares of NYSE HUM opened at $166.36 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.00 and a current ratio of 2.00. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $315.35. The firm has a market capitalization of $19.97 billion, a PE ratio of 16.94, a price-to-earnings-growth ratio of 1.81 and a beta of 0.44. The stock’s 50-day simple moving average is $189.58 and its 200-day simple moving average is $237.60.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. The firm had revenue of $32.64 billion during the quarter, compared to the consensus estimate of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, equities research analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Investors of record on Friday, March 27th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 2.1%. The ex-dividend date is Friday, March 27th. Humana’s dividend payout ratio (DPR) is currently 36.05%.

Analysts Set New Price Targets

HUM has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft set a $180.00 price objective on Humana and gave the stock a “hold” rating in a research report on Friday, February 13th. Oppenheimer set a $250.00 price target on shares of Humana in a research note on Thursday, February 12th. Royal Bank Of Canada cut shares of Humana from an “outperform” rating to a “sector perform” rating and lowered their price target for the stock from $322.00 to $189.00 in a report on Thursday, February 12th. The Goldman Sachs Group reduced their price objective on shares of Humana from $215.00 to $158.00 and set a “sell” rating on the stock in a report on Friday, February 13th. Finally, Wells Fargo & Company decreased their price objective on shares of Humana from $290.00 to $206.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 18th. Seven equities research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $225.48.

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.